Lecanemab has given us more years together. That’s not ‘minute’ nor ‘minimal’ to me,” writes one reader in STAT’s letters to ...

BridgeBio possesses a medium revenue cyclicality rating, and its operating leverage has a low rating. We assess the company's balance sheet as weak due to management's dependence on debt issuance to ...

A 75-year-old man with a genetic predisposition for Alzheimer’s has yet to show signs of the disease. Could this offer ...

A Phase III trial evaluating nex-z in transthyretin amyloidosis with cardiomyopathy is underway, with plans for another ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

These various tests are at different stages of validation – assuring they’re accurate across many different populations. And, for each protein, there are several different met ...

Now, several publications and presentations at the recent Alzheimer’s Association International Conference have demonstrated that blood tests measuring amyloid and tau proteins have become much more ...

A new biomarker test can detect early-stage tau protein clumping up to a decade before it appears on brain scans, improving ...

Art Still has ATTR amyloidosis, an inherited heart condition that dramatically impacts Black men and the former Kansas City ...

The factor that tips you over the edge from being at risk for a disease to actually developing the disease is not always ...

Researchers from Osaka University find that peristaltic pump action and high shear flow forces promote amyloid nucleation.

Researchers from Osaka University found that peristaltic pump flow mechanically breaks supersaturation to induce amyloid ...